Board summary
Key figures
62,807
Registered population
60.0% aged 18–64
22.4%
Aged 65+
ICB 19.0% · England 17.9%
5.4%
Ethnic minority (non-White)
2.3% Asian · England 9.6%
4.9%
In IMD quintile 1
ICB 31.9% · England 21.0%
~3,145
Core20 residents (est.)
see page 3
11,107
Hypertension register
+6.71% in 3 yrs · England +5.60%
718
SMI register
18.1% of Cheshire East (LAD)'s
1,342
COPD register
Reviews -4.20% in 3 yrs
Forecast to 2030
13,053
Hypertension patients, 2030
+1,946 on today
68.2%
QRISK ≥20% on statins, 2030
+1.99pp over 3 yrs
5.6%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma review rate fell over three years.
Annual asthma reviews reached 68.3% after falling 1.0% over three years (England +4.4%), leaving a scale estimate of about 1,400 of 4,363 patients unreviewed.
COPD review rate trails England after fall.
COPD annual reviews fell 4.2% over three years while England rose +2.8%, leaving coverage at 73.1% against 76.4% nationally, which could reflect recall fatigue.
Hypertension control and heart failure reviews lead.
Hypertension treated to target reaches 74.5% (England 70.3%, Cheshire East 69.8%) and annual heart failure reviews reach 85.2% (England 78.5%).
Population, age and ethnicity
Older adults comprise 22.4% of patients, exceeding England alongside 809 care home beds
Across 62,807 registered patients, 22.4% (14,081) are aged 65+, in line with Cheshire East (22.6%) but above the ICB (19.0%) and England (17.9%). Children aged 0-17 make up 17.6% (11,027) and adults aged 18-64 represent 60.0% (37,699). Census figures—reflecting resident area populations rather than registered patients—indicate 94.6% White ethnicity (Cheshire East 94.4%, ICB 93.0%, England 81.1%) and a 5.4% ethnic minority share, including 2.3% Asian or Asian British residents. List size is projected to grow 2.9% to 2030 under unverified projection methods.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Cheshire East (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Cheshire East LA) | 2,129 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 82.7% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 61.1% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Cheshire East LA) | 939 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Cheshire East LA) | 14.8 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Deprivation is low PCN-wide at 4.9% Core20 but varies across practices
The PCN average IMD decile is 6.4, compared with 7.1 in Cheshire East (LAD), 5.2 in the ICB, and 5.5 in England. The Core20 share is 4.9%, below Cheshire East (9.2%), the ICB (31.9%), and England (21.0%). Practice concentration spans 1.6 pp, from 4.5% at Park Lane Surgery to 6.2% at Broken Cross Surgery. However, resident Core20 estimates (3,145 people across two deprived LSOAs) do not reconcile with practice-level registered lists, requiring careful validation before workload targeting.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
718
SMI register
1.14% recorded prevalence
405
Learning disability register
0.64% recorded prevalence
21
Care homes, 809 beds
In the PCN catchment
8.8%
Provide unpaid care
Cheshire East (LAD), Census 2021
The PCN records 718 patients on the severe mental illness register (1.1%) and 405 with learning disabilities (0.6%), alongside 809 beds across 21 catchment care homes. Cheshire East records 10 people sleeping rough in the autumn 2025 snapshot, and the PCN has an unvalidated ceiling estimate of about 5,500 unpaid carers.
Severe mental illness: physical health checks
SMI blood pressure check coverage is 82.0% (England 83.4%), rising +0.9 pp over three years (2023 to 2025; England +4.4 pp). SMI recorded BMI is 79.5% (England 82.1%). Both indicators exceed Cheshire East (79.0% and 77.9%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
11,107
Hypertension register
+6.71%
Register growth, 3 yrs
Cheshire East (LAD) +6.54% · England +5.60%
+3.42pp
BP control, under 80
≤140/90 · +2.77pp aged 80+
+1,946
More patients by 2030
Forecast 13,053 (20.11%)
Hypertension case-finding and control
Hypertension register prevalence is 17.7% (11,107 patients), exceeding Cheshire East (17.3%), NHS Cheshire and Merseyside Integrated Care Board (16.8%), and England (15.2%). Among registered patients, 74.5% are treated to target (England 70.3%, Cheshire East 69.8%, ICB 69.1%). In addition, 90.0% have a recent blood pressure reading (England 90.0%, Cheshire East 88.4%, ICB 88.3%). Over three years (2023 to 2025), recent checks rose +0.5%, trailing Cheshire East (+2.1%), the ICB (+2.6%), and England (+3.6%). Observation periods for registers and current achievement were not captured. Slower three-year growth in blood pressure checks could reflect recall gaps, testable through practice recall audits.
Lipids and statins
Patients with QRISK ≥ 20% on lipid-lowering therapy reached 64.1%, above Cheshire East (61.2%), NHS Cheshire and Merseyside Integrated Care Board (63.2%), and England (63.6%). Three-year change rose +3.2% (2023 to 2025), trailing gains across England (+6.2%), Cheshire East (+6.3%), and the ICB (+5.2%).
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 142,660 | £1.70 | £1.71 | £1.86 | £242,522 |
| Cardiovascular (all), 2025 | 186,501 | £2.98 | £4.37 | £3.33 | £555,773 |
For lipid-regulating drugs in 2026, the PCN prescribed 142,660 items at £1.70 per item, below Cheshire East (£1.72), NHS Cheshire and Merseyside Integrated Care Board (£1.71), and England (£1.86). Across these 142,660 items, spend was £22,826 less than at England's unit cost and £1,427 less than at the ICB's unit cost.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−0.96%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+1.64%
Asthma prevalence, PCN 3-yr % change
Asthma reviews reached 68.3% (England 65.7%), but fell 1.0% over three years (2023 to 2025; England +4.4%), leaving a modelled gap of 1,384 (about 1,400) of 4,363 patients unreviewed. COPD reviews fell 4.2% (England +2.8%) to 73.1% (England 76.4%, Cheshire East 74.5%). For ages 5–19, asthma management items reached 2,011 per 1,000 (England 1,488; Cheshire East 1,586). Falling review trajectories could reflect post-pandemic recall fatigue, testable by auditing practice recall lists.
Cancer register and children's immunisation
In Q1 2025/26, 6-in-1 coverage at 12 months was 98.6% (denominator 144), exceeding the 95.0% target. At age five (cohort 122), MMR dose 1 was 96.7% while dose 2 was 91.0%, a 5.7 pp difference that sits 4 pp below the 95.0% target. Cancer register prevalence is 4.6% (2,885 patients; England 3.8%, Cheshire East 4.9%).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
Across NHS Cheshire and Merseyside ICB in 2022, 55.5% of cancers with a known stage were diagnosed at stage 1 or 2 (7,482 of 13,490 staged cases), in line with England (55.3%) but 19.5 pp below the 75.0% national ambition by 2028. A known stage was recorded for 72.8% of all registered cancers (13,490 of 18,522). Reaching the 75.0% ambition across the ICB would require about 2,640 additional early-stage diagnoses annually. Staging data is captured at ICB level rather than PCN level, describing wider system pathways rather than PCN performance. System-wide late staging increases the importance of proactive practice-level referral and safety-netting.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In provisional July 2026 data, East Cheshire NHS Trust met the 28-day faster diagnosis standard at 81.1% (standard 75.0%; England 79.3%) and the 31-day treatment standard at 96.3% (standard 96.0%; England 92.5%). However, its 62-day referral-to-treatment rate was 53.4%, below the 85.0% standard by 31.6 pp, trailing Stockport NHS Foundation Trust (74.7%), Manchester University NHS Foundation Trust (72.8%), NHS Cheshire and Merseyside Integrated Care Board (76.2%), and England (71.2%). Diagnostic waits over 6 weeks reached 26.6% for MRI and 11.5% for CT (England 21.4% and 9.9%). These acute provider figures describe wider system performance rather than PCN delivery.
| Pathways within standard (%) | East Cheshire | Stockport | Manchester | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 81.08 | 83.21 | 80.06 | 77.25 | 79.32 |
| 31-day treatment (96%) | 96.30 | 97.39 | 92.54 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 53.41 | 74.67 | 72.85 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | East Cheshire | Stockport | Manchester | England |
|---|---|---|---|---|
| MRI | 26.62 | 1.41 | 11.68 | 21.40 |
| CT | 11.49 | 2.93 | 14.66 | 9.92 |
| Echocardiography | 26.24 | 17.46 | 4.91 | 28.48 |
| Colonoscopy | 10.85 | 5.53 | 4.51 | 30.83 |
| Gastroscopy | 10.25 | 5.31 | 29.35 | 29.02 |
| All 15 DM01 tests | 16.17 | 14.08 | 8.98 | 23.14 |
| Community services activity | Cheshire East residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 72,825 | 541,280 |
| Referrals | 18,280 | 97,150 |
| Patients with a contact | 21,910 | 146,240 |
Community services (residents of Cheshire East), Jun 2026 (provisional). Provisional June 2026 Community Services Dataset records show that adults aged 65+ accounted for 60.8% of all community service contacts among Cheshire East residents (44,295 of 72,825 contacts). This activity reflects borough resident contacts rather than PCN-level service delivery, describing wider local authority demand rather than PCN performance.
Practice variation and patient experience
Practice variation and patient experience
In 2025/26, overall QOF achievement spans 93.3% at High Street Surgery to 100.0% at South Park Surgery (England 92.5%). Vaccination and immunisation domain achievement varies by 30.3 pp, from 69.7% at Park Green Surgery to 100.0% at South Park Surgery (England 55.2%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Park Lane Surgery | 108 | 4.5 | 75.2% | 67.0% | 90.5% |
| Cumberland House | 120 | 4.9 | 57.4% | 73.2% | 87.7% |
| South Park Surgery | 122 | 5.2 | 81.7% | 77.6% | 86.1% |
| Broken Cross | 88 | 6.2 | 79.0% | 59.2% | 85.1% |
| Park Green Surgery | 116 | 4.9 | 68.8% | 74.3% | 83.7% |
| High Street | 104 | 5.9 | 88.1% | 67.2% | 82.0% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Chronic disease review trajectories lag national trends despite strong current clinical achievement
Across 25 compared measures, 11 trail England's three-year trajectory. Trailing three-year changes include heart failure reviews (-1.6% versus England's +8.7%), COPD reviews (-4.2% versus +2.8%), asthma reviews (-1.0% versus +4.4%), and diabetes HbA1c control (-0.3% versus +4.4%), though current heart failure reviews (85.2% versus 78.5%) and diabetes control (61.1% versus 57.4%) exceed England. Strengths include BP control (+5.0% versus +3.2%), breast screening (+10.1% versus +8.4%), and psychosis alcohol recording (+6.8 pp versus +5.4 pp). Slowing review trajectories may indicate recall fatigue, which internal audits can verify.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
COPD reviews
Asthma reviews
Diabetes HbA1c control
Learning disability register
BP control, under 80
Breast screening (53-70)
Alcohol record (psychosis)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Cheshire East (LAD) | Asset | PCN | Cheshire East (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 21 (809 beds) | n/a | Schools (catchment) | 66 | n/a |
| Children's centres | 3 | 14 | Places of worship | 45 | 272 |
| Libraries | 2 | 16 | Day centres (VCS) | n/a | 1 |
| Children and young people (VCS) | n/a | 1 | Carers support groups (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 7 | 41 | Primary academies | 14 | 78 |
| Special schools | 1 | 5 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Asthma annual review recall
Asthma annual review coverage is 68.3% (England 65.7%), falling 1.0% over 2023 to 2025 (England +4.4%), leaving 1,384 (about 1,400) of 4,363 registered patients unreviewed. For discussion: practices could run a standardised recall search and offer flexible review slots alongside inhaler prescribing checks. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Heart failure case-finding and review
Recorded heart failure prevalence is 1.1% (661 of 62,807 patients) against 1.7% in Cheshire East and 1.1% in England, a modelled gap of +29 to +380 patients; reviews fell 1.6% over 2023 to 2025 (England +8.7%). Moderate effort to run.
Option 3
COPD annual review recovery
COPD annual review coverage is 73.1% across the 1,342-patient register, below Cheshire East (74.5%) and England (76.4%) after falling 4.2% over 2023 to 2025 (England +2.8%). For discussion: practices could run targeted recall for overdue COPD patients and raise diagnostic spirometry capacity with system partners where confirmation is needed. Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Targeted Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension recall audit (p5) | Hypertension patients with a recent blood pressure reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school MMR recall catch-up (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Early cancer diagnosis review (p7) | Cancers diagnosed at stage 1 or 2 (All cancer sites) · Cancers with a known stage (All cancer sites) | — | ICB |
| Option 1 · Asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Heart failure case-finding and review (p12) | Heart failure register · Heart Failure: QOF prevalence · Registered population | — | PCN |
| Option 3 · COPD annual review recovery (p12) | COPD register · COPD patients with a review in the last 12 months · Patients with COPD who had a review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
